Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer

Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer

We studied the short-term efficacy of alendronate, an oral bisphosphonates, on bone mineral density (BMD) during androgen deprivation therapy (ADT) in 45 nonmetastatic prostate cancer patients at the beginning of ADT (treatment group). All received alendronate five mg daily from the initiation of AD...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 54(2008), 4 vom: 30. Apr., Seite 261-6
1. Verfasser: Kawahara, Takashi (VerfasserIn)
Weitere Verfasser: Kobayashi, Takashi, Nishizawa, Koji, Kobori, Go, Mitsumori, Kenji, Ogura, Keiji
Format: Aufsatz
Sprache:English
Veröffentlicht: 2008
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Evaluation Study Journal Article Androgen Antagonists Antineoplastic Agents, Hormonal Bone Density Conservation Agents Diphosphonates Alendronate X1J18R4W8P